NASDAQ:ENGN enGene Q4 2024 Earnings Report $1.44 -0.06 (-3.69%) As of 12:43 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast enGene EPS ResultsActual EPS-$0.34Consensus EPS -$0.40Beat/MissBeat by +$0.06One Year Ago EPSN/AenGene Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AenGene Announcement DetailsQuarterQ4 2024Date12/19/2024TimeAfter Market ClosesConference Call DateThursday, December 19, 2024Conference Call Time9:30AM ETUpcoming EarningsenGene's Q2 2026 earnings is estimated for Thursday, June 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, June 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q)Annual report(10-K) enGene Earnings HeadlinesThe Little Toyota Sports Car Engine That Gave Bigger Rivals A Run For Their MoneyMay 11 at 7:40 PM | msn.comA 1.4L Chevy Spark Engine Doesn’t Sound Too Crazy Until You Put It in a PolarisMay 11 at 7:40 PM | msn.comMillionaire warns: Move your money nowLarry Benedict, the hedge fund trader who generated $274 million in profits for clients and beat the S&P 500 by 18 times in 2025, says Trump's installation of a new Federal Reserve chair is triggering the most significant shift in U.S. markets in nearly 20 years. Benedict's track record around Fed moves is hard to ignore - 62% from a single position after 2020 rate cuts, 117% in under a month when rate hikes were signaled in 2022, and an 89% gain in 17 days following a Jackson Hole speech. He has already identified the one ticker he believes will be at the center of the coming money flows, and he's sharing it free.May 12 at 1:00 AM | Brownstone Research (Ad)Pratt & Whitney clears key hurdle for XA103 engine for US’ next-gen fighter jetMay 11 at 7:40 PM | msn.comenGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in High-Risk NMIBC TranscriptMay 9 at 3:01 PM | seekingalpha.comCitizens downgrades enGene Therapeutics (ENGN)May 9 at 9:16 AM | msn.comSee More enGene Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like enGene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on enGene and other key companies, straight to your email. Email Address About enGeneenGene (NASDAQ:ENGN) is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.View enGene ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles On Holdings Sets Up for Marathon Rally: New Highs Are ComingShake Shack Stock Gets Shaken After Earnings MissRocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe?MP Materials Is Quietly Building a Rare Earth PowerhouseUbiquiti’s Uptrend Can Continue, But Don’t Rush to Buy ItAI Demand Fuels Strong Q1 Earnings for Constellation EnergyMercadoLibre Boldly Invests in Growth: Discount Deepens Upcoming Earnings Cisco Systems (5/13/2026)Alibaba Group (5/13/2026)Manulife Financial (5/13/2026)Sumitomo Mitsui Financial Group (5/13/2026)Takeda Pharmaceutical (5/13/2026)Applied Materials (5/14/2026)Brookfield (5/14/2026)National Grid Transco (5/14/2026)NU (5/14/2026)Mizuho Financial Group (5/15/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
